Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Belite Bio Starts China Trial of Therapy for Stargardt, an Inherited Renal Disease

publication date: Sep 19, 2022

Belite Bio, a San Diego subsidiary of Taiwan’s Lin Bioscience, has been approved to start China Phase III trials of its therapy for Stargardt Disease, the most commonly inherited retinal dystrophy. LBS-008 is a novel oral therapy designed as an early intervention to prevent STGD1. The global Phase III trial, which has already started in the US, the EU, Taiwan and Australia, will test the safety and efficacy of LBS-008 in adolescent STGD1 patients. Belite’s portfolio targets currently untreatable eye diseases  along with metabolic disease therapies. More details....

Stock Symbol: (NSDQ: BLTE)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital